SCHEDULE: Ally Bridge Boosts Stake in ProMIS Neurosciences

Ally Bridge Group entities have increased their beneficial ownership in ProMIS Neurosciences Inc. to 11.3% through a new securities purchase agreement.

Summary

• Ally Bridge Group entities, including Ally Bridge MedAlpha Master Fund L.P., ABG V-SIV IX Limited, and ABG V-SIV X Limited, entered into a Securities Purchase Agreement with ProMIS Neurosciences Inc. on January 29, 2026.
• The agreement is part of a larger offering by ProMIS Neurosciences Inc. to sell approximately $75 million in securities.
• The Ally Bridge Purchasers agreed to acquire 700,741 common shares at $12.13 per share.
• They also agreed to purchase warrants to acquire an additional 700,741 common shares, with an exercise price of $14.40.
• These warrants are exercisable immediately and expire on the earlier of 60 days following the public announcement of topline data from PMN310 single ascending dose cohorts or February 3, 2031.
• The final closing of this offering is expected on February 3, 2026.
• Following this transaction, the reporting persons beneficially own 6,070,405 common shares, representing 11.3% of the class.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant investment by a specialized fund provides capital and signals investor confidence in the company's prospects, particularly its PMN310 program.

Positives

• Significant investment by Ally Bridge Group, a specialized healthcare fund, indicating confidence in ProMIS Neurosciences Inc.'s prospects.
• The offering of approximately $75 million in securities provides crucial capital to the Issuer for its operations and development.

Risks

• Reporting Persons' future actions are dependent on an ongoing evaluation of the Issuer's business, financial condition, operations, prospects, and general market conditions.
• The Reporting Persons may acquire additional securities, or retain or sell all or a portion of their holdings, which could impact the Issuer's share price.
• The Reporting Persons may engage in discussions or seek to cause extraordinary corporate transactions, such as mergers, reorganizations, take-private transactions, sales or acquisitions of assets or businesses, or changes to the Issuer's capitalization, dividend policy, management, or board composition.

Future Outlook

The reporting persons acquired the securities for investment purposes and intend to continuously review their investment. They may acquire more securities, sell existing holdings, or engage in discussions with management and the board regarding potential extraordinary corporate transactions, including mergers, asset sales, or changes to the company's structure or leadership.

Industry Context

StockSavvy.ai notes that a significant investment by a specialized healthcare fund like Ally Bridge Group in a neuroscience company often signals confidence in the company's pipeline, particularly its lead candidates like PMN310. This type of strategic investment can provide crucial capital for ongoing clinical trials and development in the highly capital-intensive biotechnology sector.

Comparison to Industry Standards

• Ally Bridge Group is a prominent healthcare-focused investment firm, and their increased stake suggests a positive long-term view on ProMIS Neurosciences' potential, particularly its Alzheimer's disease program (PMN310).
• The structure of the investment, including warrants tied to a "Milestone Event" (topline data from PMN310), is a common practice in biotech financing, aligning investor interests with key clinical development achievements. This is similar to financing rounds seen in other early-to-mid-stage biotech companies like AC Immune SA or Anavex Life Sciences Corp., where funding is often contingent on or structured around clinical trial progress.
• The $12.13 per share purchase price and $14.40 warrant exercise price provide specific valuation points for this transaction, which can be compared to recent financing rounds or market prices of peer companies developing therapies for neurodegenerative diseases.

Related Party Transactions

• Ally Bridge Group entities (ABG Management Ltd., Ally Bridge Group (NY) LLC, Ally Bridge MedAlpha Master Fund L.P., Fan Yu) are the reporting persons and purchasers in the securities agreement.

Stakeholder Impact

• Shareholders: Potential dilution from the new share issuance, but also a capital infusion for the company and a vote of confidence from a major investor. The possibility of future extraordinary corporate transactions (merger, take-private) could significantly impact shareholder value.
• Company (ProMIS Neurosciences Inc.): Receives capital to fund operations and development, particularly for PMN310.

Next Steps

• Final closing of the offering expected on February 3, 2026.
• Public announcement of topline data from PMN310 single ascending dose cohorts (Milestone Event for warrant expiration).
• Reporting Persons will continue to review their investment and may engage in further transactions or discussions regarding corporate strategy.

Key Dates

Recommendation

While the investment by Ally Bridge Group is a positive signal and provides capital, the filing is primarily an ownership disclosure. It doesn't provide new operational or financial results from ProMIS Neurosciences Inc. that would warrant a strong buy or sell. The future actions of the reporting persons, including potential sales or strategic changes, introduce an element of uncertainty. Therefore, a "hold" recommendation is appropriate, advising investors to monitor the company's clinical progress (especially PMN310 data) and any further actions by this significant shareholder.

Keywords

ProMIS Neurosciences, Ally Bridge Group, Securities Purchase Agreement, Warrants, PMN310, Biotechnology, Neuroscience, Investment, Schedule 13D, Equity Financing